American pharmaceutical and biotechnology company Pfizer has agreed to acquire cancer drugmaker Seagen (formerly Seattle Genetics) for $229 per share or $43 billion in cash, in a move to strengthen its position in the oncology space. With the proposed acquisition, Pfizer anticipates broadening its oncology portfolio by adding Seagen’s medicines, late-stage development programs, and antibody-drug […]
American biotechnology company Seagen (formerly Seattle Genetics) has received accelerated approval from the US Food and Drug Administration (FDA) for the company’s oral drug Tukysa (tucatinib) in combination with trastuzumab. Tukysa in combination with trastuzumab is indicated for the treatment of adult patients with RASwild-type, HER2-positive unresectable or metastatic colorectal cancer, which has advanced following […]
US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major pharma companies will develop and commercialize Seattle Genetics’ ladiratuzumab vedotin across the world. Ladiratuzumab vedotin is an investigational antibody-drug conjugate (ADC) that targets LIV-1, which is presently in phase 2 […]
Takeda Pharmaceutical has secured extended approval for ADCETRIS (brentuximab vedotin) in the European Union to include the treatment of previously untreated systemic anaplastic large cell lymphoma (sALCL) in adult patients. The approval from the European Commission (EC) is for the combination of ADCETRIS with CHP (cyclophosphamide, doxorubicin, prednisone. It comes in the wake of a […]
PADCEV, KEYTRUDA combination : Astellas Pharma and Seattle Genetics said that the combination of PADCEV (enfortumab vedotin-ejfv) and Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) has been given breakthrough therapy designation from the US Food and Drug Administration (FDA) in first-line advanced bladder cancer. The FDA breakthrough therapy status for PADCEV, KEYTRUDA combination is for the treatment […]
Padcev FDA approval : Astellas Pharma and Seattle Genetics have bagged accelerated approval from the US Food and Drug Administration (FDA) for Padcev (enfortumab vedotin-ejfv) for the treatment of advanced urothelial cancer, the most common form of bladder cancer. Padcev, which has been co-developed by the two pharma companies, is a Nectin-4-directed antibody and microtubule […]
The European Commission (EC) has officially expanded the approval of Takeda Pharmaceutical’s ADCETRIS (brentuximab vedotin) to include the treatment of previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with AVD (Adriamycin, vinblastine, and dacarbazine) for adult patients. This new approval is a significant milestone for both Takeda and the Hodgkin lymphoma community, as it […]
Seattle Genetics’ Adcetris, in combination with CHP chemotherapy, gains FDA approval for treating certain types of peripheral T-cell lymphoma. Seattle Genetics has announced that the U.S. Food and Drug Administration (FDA) has granted approval for its monoclonal antibody Adcetris (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone). This new approval is specifically for […]
Seattle Genetics, a leader in oncology biotechnology, has announced the acquisition of Cascadian Therapeutics for approximately $614 million, a strategic move to enhance its portfolio of solid tumor treatments. The acquisition, which involves Seattle Genetics paying $10 per share in cash for the California-based company, is set to significantly advance its research in cancer therapies, […]